Advanced Ag Protection LLC
Total Consideration
$32.5M
Purchase-Price Allocation
Goodwill
$21.8M
2 years of history · ending 2025-12-31 · SEC EDGAR
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | — | -3.06% | 1.14% | 0.69% | 0.32% | 0.41% |
| Foreign Rate Differential | — | — | — | — | — | — |
| Other Adjustments | -5.67% | -0.18% | 0.00% | 0.26% | 0.50% | 0.45% |
| SBC (Nondeductible) | -24.44% | -1.87% | 0.23% | 1.47% | 0.28% | 0.22% |
| Valuation Allowance Change | 9.63% | 3.85% | -0.28% | -0.40% | 0.08% | 0.04% |
| Tax Law Change | — | — | — | — | — | — |
| Effective Tax Rate | -0.54% | 19.76% | 22.77% | 23.58% | 22.23% | 22.22% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | −$34.0K | $11.3M | $15.4M | $24.4M | $33.6M | $56.3M |
| Income Taxes Paid (Cash) | $7.2M | $2.1M | $18.9M | $21.1M | $38.5M | $59.1M |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Total Consideration
$32.5M
Purchase-Price Allocation
Goodwill
$21.8M
Total Consideration
$29.5M
Purchase-Price Allocation
Goodwill
$4.9M
Total Consideration
$311.0K
Per-case litigation disclosures sourced from us-gaap:LossContingenciesByNatureOfContingencyAxis dimensional XBRL. Coverage is sparse — most filers aggregate at the parent level (JNJ talc, PFE opioid) — but high-value when per-case disclosure exists. Loss estimate is either a single point or a low/high range, depending on how the issuer values the contingency.
As of 2025-12-31
| Case | Estimated Loss | Damages Sought | Settlement |
|---|---|---|---|
| Standby Letters Of Credit | $4M | — | — |
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).